<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396721</url>
  </required_header>
  <id_info>
    <org_study_id>SIREPNA/05</org_study_id>
    <secondary_id>2005-002610-37</secondary_id>
    <nct_id>NCT00396721</nct_id>
  </id_info>
  <brief_title>Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy</brief_title>
  <acronym>SIREPNA</acronym>
  <official_title>Pilot Trial of Treatment of Poor-Prognosis IgA Nephropathy With Low Exposure to Sirolimus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Josep m Cruzado</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test in a pilot trial the efficacy and tolerance of sirolimus
      oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of the administration of Rapamune on a clinical composite variable (change in proteinuria, blood pressure and hematuria) in patients with IgA nephropathy with poor prognosis criteria</measure>
    <time_frame>at month 12th</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the glomerular filtrate rate evaluated by means of radionuclide techniques (51Cr-EDTA) and comparison between both arms</measure>
    <time_frame>At months 6th and 12th</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal histology</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who withdraw from the study medication due to adverse events</measure>
    <time_frame>Within 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with therapeutic failure</measure>
    <time_frame>Within 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Glomerulonephritis, IGA</condition>
  <condition>Nephropathy, IGA</condition>
  <condition>IGA Nephropathy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor + statin</intervention_name>
    <description>sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus (study drug)+ACE inhibitor + statin</intervention_name>
    <description>enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 70 and with capacity to grant informed consent

          -  Biopsy-proven IgA nephropathy by means of standard immunohistochemical and
             morphological criteria

          -  Renal biopsy in the in the 3 months prior to randomization date

          -  Absence of known hepatic, cardiac, pulmonary or intestinal disease

          -  Glomerular filtrate estimated by Cockcroft-Gault, more than 30 ml/min

          -  Any of the following clinical states: a) High blood pressure defined as systolic blood
             pressure higher than 140 mmHg or diastolic blood pressure higher than 90 mmHg
             associated with proteinuria between 0.3-1 g/day and/or microhematuria. b) Proteinuria
             higher than 1g/day

          -  Women of child-bearing age will follow a suitable contraceptive method, and a negative
             pregnancy test will be needed before inclusion in the study

        Exclusion Criteria:

          -  Serology positive for HIV or hepatitis B infection (defined as positive for the HbsAg
             antigen) or hepatitis C infection (defined as viral RNA detection)

          -  Treatment with steroids or immunosuppressors in the two previous years

          -  Evidence of active infection at the time of inclusion in the study

          -  Pregnancy or breastfeeding at the time of inclusion in the study

          -  Estimated glomerular filtration &lt; 30 ml/min, bilirubin &gt; 2 mg/dl, or ALT or AST two
             times higher than the normal upper limit

          -  Diabetes Mellitus, defined as patients treated with insulin or oral antidiabetics or
             glycemias higher than 140 mg/dl in two or more episodes

          -  Poor control of high blood pressure (defined as systolic blood pressure greater than
             160 mm Hg or diastolic blood pressure greater than 100 mm Hg, taking 3 or more
             antihypertensives) or evidence or suspicion of renovascular disease

          -  Thrombocytopenia less than 100,000 /mm3 or total neutrophil value lower than 2000 /mm3
             or triglycerides value &gt; 400 mg/dL (4.6 mmol/L) or cholesterol &gt; 300 mg/dL (7.8
             mmol/L) or LDL &gt; 200 mg/dL

          -  IgA nephropathy systemic forms, i.e., Schönlein-Henoch purpura, IgA nephropathy
             secondary forms, post-renal transplant IgA nephropathy recurrences, cases presented in
             the form of rapidly progressive renal failure and cases with the presence of cellular
             crescents in more than 50% of the glomeruli will be excluded

          -  History of cancer in the previous 5 years,exception of skin basocellular carcinoma and
             uterine in situ carcinoma (completely removed both of them)

          -  Know intolerance to Sirolimus or macrolides
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep M Cruzado, Medical Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Nephrlogy Department. Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meritxell Ibernon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JORDI BALLARÍN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FUNDACIÓ PUIGVERT DE BARCELONA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology Department. Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bellvitgehospital.cat/</url>
    <description>This is the center in Spain for the central contact and the main location including patients.</description>
  </link>
  <reference>
    <citation>Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002 Sep 5;347(10):738-48. Review.</citation>
    <PMID>12213946</PMID>
  </reference>
  <reference>
    <citation>Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med. 1994 Nov 3;331(18):1194-9.</citation>
    <PMID>7935657</PMID>
  </reference>
  <reference>
    <citation>Wu H, Clarkson AR, Knight JF. Restricted gammadelta T-cell receptor repertoire in IgA nephropathy renal biopsies. Kidney Int. 2001 Oct;60(4):1324-31.</citation>
    <PMID>11576346</PMID>
  </reference>
  <reference>
    <citation>Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol. 2005 Jul;16(7):2063-72. Epub 2005 May 25.</citation>
    <PMID>15917339</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2006</study_first_submitted>
  <study_first_submitted_qc>November 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2006</study_first_posted>
  <last_update_submitted>September 14, 2011</last_update_submitted>
  <last_update_submitted_qc>September 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Josep m Cruzado</investigator_full_name>
    <investigator_title>Nephrologist</investigator_title>
  </responsible_party>
  <keyword>Nephropathy, IGA</keyword>
  <keyword>Pilot trial</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Rapamune</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

